Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome

Inclusion Criteria

• •1. Provide voluntary, written informed consent (parent(s) / legal guardian(s) of patient); provide voluntary, written assent (subjects, as appropriate)
• •2. Participant must:
• •1. Have participated in and completed the Study C602 Randomized Withdrawal (RW) Period;
• •2. Have participated in but discontinued from the Study C602 RW Period and at least 16 weeks have elapsed since the date of their randomization into the C602 RW Period; or
• •3. Have participated in Study C602 OLE period, did not consent to participate in the RW Period, and at least 16 weeks have elapsed since the date of their C602 Open-Label Extension End of Treatment Visit.